Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
3 August 2017
Answer given by Ms Bieńkowska on behalf of the Commission

The Commission supports the transition to a modern, clean and fair economy, with a comprehensive and results-oriented approach across different policy areas, providing sector-specific solutions when needed.

With regard to the pharmaceutical industry, the Commission is currently conducting a number of initiatives aiming to improve the competitiveness and innovation framework, for example in respect of activities related to the Transparency Directive(1) and the committee established under that directive(2).

The Commission has acknowledged the importance of intellectual property protection for the pharmaceutical sector and included a package of dedicated measures in the 2015 Single Market Strategy(3). In that context, the Commission has launched a study analysing the impact of pharmaceutical incentives on innovation, availability and accessibility of medicinal products, in response to the call by the Council in 2016(4). The study is being carried out in the course of 2017.

Finally, the Commission will organise another multi-stakeholder workshop as a follow-up to the Process on Corporate Responsibility in the Field of Pharmaceuticals(5), bringing together Member States, healthcare professionals, patients, and industry to discuss matters such as pricing and reimbursement.

(1)Council Directive 89/105/EEC relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems.
(2)The next meeting of this Consultative Committee is scheduled for September 2017.
(3)Such as the evaluation of the EU's 20-year old acquis on supplementary protection certificates (SPC) for pharmaceutical products, an examination of the merits of an SPC manufacturing waiver for export purposes and the possible creation at some point of a unitary SPC for the unitary patent.
(4)Council conclusions on strengthening the balance in the pharmaceutical systems in the EU and its Member States: http://www.consilium.europa.eu/en/press/press-releases/2016/06/17-epsco-conclusions-balance-pharmaceutical-system/

Last updated: 4 August 2017Legal notice